MedTrace Logo

Intravenous Infusion of Human Mesenchymal Stem Cells (HMM910 ) in Postmenopausal Women With Osteoporosis at High Risk of Fracture

NCT06949137 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-02-10

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the safety and tolerability of human umbilical cord-derived mesenchymal stem cells for injection (HMM910 ) in postmenopausal women with osteoporosis who are at high risk of fracture.

Conditions

Interventions

BIOLOGICAL

Human Umbilical Cord-derived Mesenchymal stem cell

Intravenous infusion of human mesenchymal stem cells (HMM910 ) at 20-25 drops per minute

Sponsors & Collaborators

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

    collaborator OTHER

  • Help Therapeutics

    lead INDUSTRY

Principal Investigators

  • Juan Li, MD, PhD · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

  • Hua Lin, MD · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
45 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2026-03-06
Completion
2026-09-06

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06949137 on ClinicalTrials.gov